Drug Profile
Cofirasersen - Ionis Pharmaceuticals
Alternative Names: ENaC ASO - Ionis Pharmaceuticals; Generation 2.5 ENaC antisense oligonucleotide - Ionis Pharmaceuticals; Generation 2.5 ENaC ASOs - Ionis Pharmaceuticals; ION-827359; IONIS-ENAC-2.5Rx; IONIS-ENaCRxLatest Information Update: 04 Jul 2021
Price :
$50
*
At a glance
- Originator Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Epithelial sodium channel antagonists; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 14 May 2021 Pharmacokinetics and safety data from a phase I/IIa trial in Cystic fibrosis presented at the International Conference of the American Thoracic Society (ATS-2021)
- 13 May 2021 Ionis Pharmaceuticals terminates phase II trial in Chronic obstructive pulmonary disease in United Kingdom, Germany, Hungary and Czech Republic (Inhalation) (NCT04441788)
- 04 Feb 2021 Ionis Pharmaceuticals completes a phase I/IIa trial in Cystic fibrosis in Germany and United Kingdom (Inhalation) (NCT03647228) (EudraCT2018-002621-27)